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Alternative treatments to inhibit VEGF in age-related 
choroidal neovascularisation: 2-year ﬁ ndings of the IVAN 
randomised controlled trial
Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan M Downes, Andrew J Lotery, Lucy A Culliford, Barnaby C Reeves, on behalf of the 
IVAN study investigators*
Summary 
Background Bevacizumab has been suggested to have similar eﬀ ectiveness to ranibizumab for treatment of 
neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation 
(IVAN) trial was designed to compare these drugs and diﬀ erent regimens. Here, we report the ﬁ ndings at the 
prespeciﬁ ed 2-year timepoint.
Methods In a multicentre, 2×2 factorial, non-inferiority randomised trial, we enrolled adults aged at least 50 years 
with active, previously untreated neovascular age-related macular degeneration and a best corrected distance visual 
acuity (BCVA) of at least 25 letters from 23 hospitals in the UK. Participants were randomly assigned (1:1:1:1) to 
intravitreal injections of ranibizumab (0·5 mg) or bevacizumab (1·25 mg) in continuous (every month) or 
discontinuous (as needed) regimens, with monthly review. Study participants and clinical assessors were masked to 
drug allocation. Allocation to continuous or discontinuous treatment was masked up to 3 months, at which point 
investigators and participants were unmasked. The primary outcome was BCVA at 2 years, with a prespeciﬁ ed non-
inferiority limit of 3·5 letters. The primary safety outcome was arterial thrombotic event or hospital admission for 
heart failure. Analyses were by modiﬁ ed intention to treat. This trial is registered, number ISRCTN92166560.
Findings Between March 27, 2008, and Oct 15, 2010, 628 patients underwent randomisation. 18 were withdrawn; 
610 received study drugs (314 ranibizumab; 296 bevacizumab) and were included in analyses. 525 participants 
reached the visit at 2 years: 134 ranibizumab in continuous regimen, 137 ranibizumab in discontinuous regimen, 
127 bevacizumab in continuous regimen, and 127 bevacizumab in discontinuous regimen. For BCVA, bevacizumab 
was neither non-inferior nor inferior to ranibizumab (mean diﬀ erence −1·37 letters, 95% CI −3·75 to 1·01; p=0·26). 
Discontinuous treatment was neither non-inferior nor inferior to continuous treatment (−1·63 letters, –4·01 to 0·75; 
p=0·18). Frequency of arterial thrombotic events or hospital admission for heart failure did not diﬀ er between groups 
given ranibizumab (20 [6%] of 314 participants) and bevacizumab (12 [4%] of 296; odds ratio [OR] 1·69, 
95% CI 0·80–3·57; p=0·16), or those given continuous (12 [4%] of 308) and discontinuous treatment (20 [7%] of 302; 
0·56, 0·27–1·19; p=0·13). Mortality was lower with continuous than discontinuous treatment (OR 0·47, 
95% CI 0·22–1·03; p=0·05), but did not diﬀ er by drug group (0·96, 0·46–2·02; p=0·91).
Interpretation Ranibizumab and bevacizumab have similar eﬃ  cacy. Reduction in the frequency of retreatment resulted 
in a small loss of eﬃ  cacy irrespective of drug. Safety was worse when treatment was administered discontinuously. 
These ﬁ ndings highlight that the choice of anti-VEGF treatment strategy is less straightforward than previously thought.
Funding UK National Institute for Health Research Health Technology Assessment programme.
Introduction
Neovascular age-related macular degeneration is a 
common bilateral condition that aﬀ ects people aged 
50 years and older, and causes severe impairment of 
central vision. Intravitreal treatment with ranibizumab, 
an anti body to vascular endothelial growth factor 
(VEGF), was shown to be eﬀ ective in neovascular age-
related macular degeneration compared with photo-
dynamic therapy or no treatment.1,2 Anti-VEGF drugs 
were thus established as a standard of care for neo-
vascular age-related macular degeneration.3–6
Bevacizumab, an antibody to VEGF that is licensed for 
treatment of bowel cancers, is the parent molecule from 
which ranibizumab was developed. Small non-ran domised 
studies7–9 done while ranibizumab was awaiting marketing 
authorisation suggested that bevacizumab had similar 
eﬀ ectiveness to ranibizumab for treatment of neovascular 
age-related macular degeneration. These ﬁ ndings were 
important, because every dose of rani bizumab is expensive 
and treatment can be needed every month for 
several years.3–6 The dose at which bevacizumab is supplied 
is suﬃ  ciently large to allow aliquoting into many smaller 
fractions for intra ocular administration, thus oﬀ ering 
large cost savings. Its use oﬀ  licence, given in a similar way 
to ranibizumab, has spread rapidly across the world.
The absence of robust information about the safety of 
bevacizumab in the treatment of neovascular age-related 
macular degeneration and uncertainty about treatment 
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frequency for both bevacizumab and ranibizumab led us 
to undertake the Inhibition of VEGF in Age-related 
choroidal Neovascularisation (IVAN) trial in the UK.4 
The Comparison of Age-related macular degeneration 
Treat ments Trials (CATT) were developed in parallel in 
the USA.3,5
We reported an interim analysis after 1 year of follow-
up in 2012, and a pooled analysis of the IVAN and CATT 
1-year data.4 These analyses showed that functional 
outcomes were similar between the two drugs and 
between monthly (continuous) and intermittent treat-
ment administration (as needed or discontinuous) but 
that the risk of a systematic serious adverse event (SAE) 
was higher with bevacizumab than ranibizumab. Here, 
we report the deﬁ nitive ﬁ ndings of the IVAN trial at the 
prespeciﬁ ed primary 2-year timepoint and meta-analyses 
pooling key outcomes from both trials after 2 years.
Methods
Study design and participants
We undertook a multicentre, 2×2 factorial, non-inferiority 
randomised trial in 23 teaching and general hospitals in 
the UK (appendix). Full inclusion and exclusion criteria 
have been reported previously.4 Brieﬂ y, adults aged at 
least 50 years with active, previously untreated neo-
vascular age-related macular degeneration in the eye 
designated as the study eye and a best corrected distance 
visual acuity (BCVA) of at least 25 letters on a standard 
vision chart were eligible to participate.4 Participants 
provided written informed consent. A UK National 
Health Service Research Ethics Committee approved the 
trial (07/NIR03/37).
Randomisation and masking
Participants were randomly assigned (1:1:1:1) to one of 
four groups in a factorial design: ranibizumab or 
bevacizumab in continuous or discontinuous regimens. 
Randomisation was stratiﬁ ed by centre and was blocked 
to ensure roughly equal numbers of participants per 
group within a centre. Allocations were computer 
generated and concealed with an internet-based system 
(Sealed Envelope, London, UK). Staﬀ  in participating 
centres accessed the website and, on entering information 
to conﬁ rm a participant’s identity and eligibility, were 
provided with the unique study number. Study 
participants and clinical assessors (nurses, optometrists, 
imaging technicians, and clinicians) were masked to 
drug allocation. Study drugs were dispensed by pharmacy 
staﬀ  who were unmasked, but had no other role in the 
study. Most IVAN sites used a separate unmasked clinical 
team consisting of a nurse and a clinician to administer 
treatment; this team did not take part in any other study 
procedures. At nine sites, staﬀ  were insuﬃ  cient to have 
masked and unmasked teams; here, an unmasked nurse 
withdrew ranibizumab from the vial into a syringe so 
that the ﬁ nal appearance of the preparation was identical 
to that of the syringe containing preﬁ lled bevacizumab. 
All random allocations, including to continuous or 
discontinuous treatment, were prepared at the outset. 
Allocation to continuous or discontinuous treatment was 
masked up to 3 months, at which point both investigator 
and participant were unmasked. Lesion morphology was 
assessed by independent graders, who were masked to 
drug and treatment regimen, in the UK Network of 
Ophthalmic Reading Centres.
Procedures
Participants received intravitreal injections of rani-
bizumab (0·5 mg) or bevacizumab (1·25 mg).2,10,11 Both 
drugs were procured commercially. The compounding 
pharmacy at the Royal Liverpool and Broadgreen 
University Hospitals NHS Trust (Liverpool, UK) was 
contracted to supply the study drugs. Bevacizumab was 
purchased from Roche and prepared for intraocular 
administration. The pharmacy used a range of standard 
and non-standard tests to establish stability, potency, and 
sterility of bevacizumab after aliquoting or storage, or 
both.12,13 Because the most convenient method of 
dispensing aliquoted bevacizumab is in a preﬁ lled syringe, 
the drug was stored in sterile polycarbonate syringes, 
secured with Luer-Lok tip caps for up to 90 days at a 
temperature of 2–8°C. Stability of the drug was conﬁ rmed 
by tests of molecular weight and electric charge by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) under non-denaturing and denaturing conditions, 
reverse-phase high-performance liquid chromatography, 
and size exclusion chroma tography. ELISA was used to 
conﬁ rm binding of the drug to VEGF after storage. Tests 
were done to simulate conditions of transportation, in 
which syringes were shaken vigorously for up to 6 h at 
room temperature. The stored drug was subjected to 
micro scopic analysis and culture for microorganisms by 
serial sampling. The results showed that the drug 
remained stable and sterile under the conditions 
described. The pharmacy followed strict standard operat-
ing procedures and guidelines for manufacture that were 
submitted to and approved by the UK Medicines and 
Healthcare products Regulatory Agency.
Participants underwent clinical examination, optical 
coherence tomography (OCT), and fundus photography 
every month (28–35 days). They received study injections 
at visits 0, 1, and 2. Participants assigned to the con-
tinuous regimen were treated monthly thereafter. 
Participants assigned to the discontinuous regimen were 
not retreated after visit 2 unless prespeciﬁ ed clinical and 
OCT criteria for active disease were met.4 If retreatment 
was needed, a further cycle of three doses was given 
monthly. Prompted by the ﬁ ndings from CATT at 
2 years,5 colour and OCT images at baseline and most 
recent available follow-up were regraded after the end of 
follow-up, speciﬁ cally to identify any new geographic 
atrophy lesions that had developed during the trial. 
Participants were followed up for 2 years. Exit visits 
before 2 years occurred only when a participant chose to 
For the trial protocol see http://
www.hta.ac.uk/1625
See Online for appendix
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leave the study early or was withdrawn by a partici-
pating ophthalmologist.
Our objective was to test the non-inferiority of bevaci-
zumab to ranibizumab and of the discontinuous to the 
continuous regimen. The primary outcome was BCVA 
(number of letters read on a standard early treatment 
diabetic retinopathy study chart at 2 years14). Secondary 
outcomes were additional visual function measures 
(contrast sensitivity,15 near visual acuity,16 and reading 
index17), lesion morphology and metrics from angiograms 
and OCTs, generic and vision-speciﬁ c health-related 
quality of life (EQ-5D,18 MacDQoL,19 and MacTSQ20), 
adverse events, cumulative resource use or cost and cost-
eﬀ ectiveness, and survival free from treatment failure. 
Results of the cost analyses and for survival free from 
treatment failure will be reported elsewhere.
BCVA was measured every 3 months. Most of the other 
outcomes were measured at baseline and visits 3, 6, 12, 
18, and 24. Lesion area was measured at baseline, and 
visits 12 and 24. EQ-5D was measured at baseline, and 
visits 3, 12, and 24. MacDQoL and MacTSQ were 
measured at visits 3, 12, and 24.
Adverse events were recorded at each visit and coded 
with the Medical Dictionary for Regulatory Activities 
(version 14.1). All SAEs were reviewed by senior clinicians 
(UC, SPH, SMD, and AJL), who were masked to 
treatment allocation. The primary safety outcome was 
the occurrence of an arterial thrombotic event (as deﬁ ned 
by the Antiplatelet Trialists’ Collaboration21) or hospital 
admission for heart failure.
Statistical analysis
We speciﬁ ed a non-inferiority limit of 3·5 letters for 
distance BCVA, assuming no interaction between drug 
and treatment regimen. The target sample size was 600, 
which would give 90% power to detect non-inferiority 
(signiﬁ cance 2·5%, one-sided).4
Modiﬁ ed intention-to-treat analyses were directed by a 
pre speciﬁ ed analysis plan. All participants who received 
at least one dose of allocated drug were included in 
analyses. We compared drugs and dosing regimens with 
logistic regression (binary variables) and linear mixed 
model regression (continuous variables), except when 
otherwise noted. Analyses were adjusted for centre size 
(seven strata), combining adjacent strata if necessary to 
ensure estimation. For continuous variables measured at 
baseline, we modelled values jointly to avoid having to 
exclude or impute cases with missing baseline measures. 
We ﬁ tted interactions with follow-up time and describe 
diﬀ erences between groups at 2 years. We checked model 
validity with recommended graphical methods.22 When a 
model ﬁ tted poorly, we explored transformations. Out-
comes analysed on a logarithmic scale were trans formed 
back to the original scale after analysis and results are 
presented as geometric mean ratios. Odds ratios were 
used for comparisons of EQ-5D, lesion area, and MacTSQ 
at 2 years, for which we were unable to identify a suitable 
trans formation; we dichotomised data and adjusted 
analyses for baseline value when obtained. We compared 
num bers of SAEs by drug and treatment regimen when 
more than ten participants experienced the event. We 
used likelihood ratio tests to establish signiﬁ cance.
Results are reported as eﬀ ect estimates with 95% CIs. 
We report comparisons between drugs separately for 
continuous and discontinuous regimens only when the 
interaction of drug and dosing regimen reached a 
prespeciﬁ ed level of signiﬁ cance (5% for total lesion 
thickness at the fovea and presence of ﬂ uid on OCT, for 
which CATT suggested a possible interaction;3 1% 
otherwise).
Previous meta-analyses have been reported.23,24 We 
adapted the search strategy used by Mitchell24 (who 
identiﬁ ed one head-to-head trial report ing outcomes to 
1 year25) and noted that 2-year ﬁ ndings were reported 
only for CATT.5 We combined changes in BCVA at 2 years 
from baseline in CATT and the IVAN trial in a ﬁ xed-
eﬀ ects meta-analysis. We used weighted mean 
diﬀ erences to account for study size. We investi gated 
mortality, arterial thrombotic events, occur rence of at 
least one serious adverse event, which were all avail able 
to only 1 year by treatment regimen for CATT. 
Additionally, we investigated change in total lesion 
thickness at the fovea, and new geographic atrophy. We 
combined changes because the primary CATT analyses 
reported change analyses. The analyses of the safety data 
and geographic atrophy used raw frequency counts.
Analyses were done with Stata (version 12.1) and SAS 
(version 9.3).
This trial is registered, number ISRCTN92166560.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Between March 27, 2008, and Oct 15, 2010, we randomised 
628 patients to ranibizumab or bevacizumab. 18 were 
withdrawn, leaving 610 who received the study drugs and 
were included in analyses (appendix). Participants’ 
baseline characteristics were similar across the groups 
(appendix). Nine participants were identiﬁ ed as ineligible 
after images submitted at time of recruitment were graded, 
but were nevertheless included.4 Ophthal mologists 
reported not knowing which drug participants were 
receiving at visit 3 on 555 (98%) of 567 occasions, at visit 12 
on 514 (99%) of 521 occasions, at visit 24 on 506 (99%) of 
512 occasions, and at exit visit on all 22 occasions. 
Participants reported not knowing which drug they were 
receiving at visit 3 on 560 (99%) of 564 occasions, at visit 12 
on 509 (99%) of 516 occasions, at visit 24 on 499 (98%) of 
510 occasions, and at exit visit on all 21 occasions.
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Some protocol deviations were recorded (appendix). 
The wrong study drug was given on two (<1%) of 
12 761 follow-up visits, and treatment regimens were not 
adhered to on 133 visits (1%). Overall, 350 participants 
(57%) missed at least one visit, including those who 
died or withdrew early. However, 12 761 (87%) of 
14 640 scheduled visits were attended, and the analysis 
methods meant that most participants could be included.
525 participants reached the visit at 2 years (table 1). 
BCVA at 2 years was similar between ranibizumab and 
bevacizumab groups and con tinu ous and discontinuous 
treatment groups (table 1). Bevacizumab was neither 
inferior nor non-inferior to ranibizumab because the 
95% CIs include zero and the non-inferiority margin 
(ﬁ gure 1). Similarly the discontinuous regimen was 
neither inferior nor non-inferior to the continuous 
regimen. Therefore, the primary hypotheses about the 
non-inferiority of dis continuous bevacizumab to con-
tinuous ranibizumab were not supported.
Near visual acuity, reading index, and contrast sensi-
tivity after 2 years did not diﬀ er signiﬁ cantly between 
drug groups (ﬁ gure 2, table 1). However, near visual 
acuity and contrast sensitivity were signiﬁ cantly worse 
with the discon tinuous regimen (ﬁ gure 2, table 1). Total 
Figure 1: Mean diﬀ erences in best corrected distance visual acuity at 2 years
By drug (top) and by regimen (bottom). Black dashed line shows non-inferiority limit of –3·5 letters. Mean 
diﬀ erences estimated with data from visits 0, 3, 6, 9, 12, 15, 18, 21, and 24, adjusted for centre size. 95% CIs given 
in parentheses and shown by bars.
–1·37 (–3·75 to 1·01), p=0·26
Favours ranibizumab Favours bevacizumab
0
Letters
1 2 3–4 –3 –2 –1 4
–1·63 (–4·01 to 0·75), p=0·18
Favours continuous Favours discontinuous
0
Letters
1 2 3–4 –3 –2 –1 4
Mean diﬀerence
Ranibizumab
(n=271)
Bevacizumab
(n=254)
Continuous regimen 
(n=261)
Discontinuous regimen 
(n=264)
Overall
(n=525)
Best corrected distance visual acuity (letters)* 67·8 (17·0) 66·1 (18·4) 66·6 (17·9) 67·3 (17·5) 67·0 (17·7)
Number of treatments† 18 (11 to 23) 19 (12 to 23) 23 (21 to 24) 13 (8 to 17) 18 (12 to 23)
Near visual acuity (log[minimum angle of resolution])‡ 0·55 (0·39) 0·61 (0·42) 0·58 (0·40) 0·58 (0·41) 0·58 (0·41)
Reading index (words read per min divided by print 
font size)§
50·90 (22·80 to 93·70) 52·50 (9·70 to 90·60) 46·30 (11·40 to 84·00) 55·35 (19·00 to 97·60) 52·00 (15·60 to 93·60)
Reading test not performed due to very poor vision¶ 8/249 (3%) 2/235 (1%) 3/245 (1%) 7/239 (3%) 10/484 (2%)
Contrast sensitivity (letters)|| 28·08 (6·00) 28·30 (5·75) 28·65 (5·40) 27·72 (6·30) 28·19 (5·88)
Total lesion thickness at fovea (μm)** 322·4 (137·3) 331·0 (144·2) 314·7 (137·1) 338·5 (143·3) 326·6 (140·6)
Retinal thickness plus subretinal ﬂ uid at fovea (μm)†† 163·5 (77·7) 172·7 (95·7) 161·7 (84·2) 174·4 (89·4) 168·0 (87·0)
Any ﬂ uid on optical coherence tomography‡‡
Absent 127/256 (50%) 100/243 (41%) 135/249 (54%) 92/250 (37%) 227/499 (45%)
Present 127/256 (50%) 141/243 (58%) 112/249 (45%) 156/250 (62%) 268/499 (54%)
Cannot grade 2/256 (1%) 2/243 (1%) 2/249 (1%) 2/250 (1%) 4/499 (1%)
Dye leakage on angiogram§§
Absent 146/250 (58%) 145/236 (61%) 155/244 (64%) 136/242 (56%) 291/486 (60%)
Present 101/250 (40%) 89/236 (38%) 86/244 (35%) 104/242 (43%) 190/486 (39%)
Cannot grade 3/250 (1%) 2/236 (1%) 3/244 (1%) 2/242 (1%) 5/486 (1%)
Neovascular lesion
Area of lesion (optic disc area) ¶¶ 0·38 (0·00 to 3·78) 0·43 (0·00 to 3·25) 0·06 (0·00 to 2·87) 0·59 (0·00 to 4·38) 0·39 (0·00 to 3·54)
Present|||| 142/246 (58%) 127/234 (54%) 123/241 (51%) 146/239 (61%) 269/480 (56%)
New geographic atrophy†*** 86/305 (28%) 91/291 (31%) 101/301 (34%) 76/295 (26%) 177/596 (30%)
EQ-5D score††† 0·85 (0·73 to 1·00) 0·85 (0·73 to 1·00) 0·85 (0·73 to 1·00) 0·85 (0·73 to 1·00) 0·85 (0·73 to 1·00)
MacDQOL score‡‡‡ −1·5 (−2·8 to −0·3) −1·4 (−2·7 to −0·4) −1·3 (−2·7 to −0·3) −1·6 (−3·0 to −0·4) −1·4 (−2·7 to −0·3)
MacTSQ score§§§ 66 (61·5 to 70·0) 65 (60·0 to 69·0) 65·5 (61·0 to 69·0) 66 (60·0 to 69·0) 66 (61·0 to 69·0)
Data are mean (SD), median (IQR), or n/N (%). 525 patients who reached visit 24 at 2 years included, unless otherwise stated. *Data missing for eight patients (one given ranibizumab in continuous 
regimen; two given ranibizumab in discontinuous regimen; one given bevacizumab in continuous regimen; four given bevacizumab in discontinuous regimen).†All study participants (n=610) 
included in analysis. ‡Data missing for 26 patients (six; nine; ﬁ ve; six). §Data missing for 41 patients (nine; 13; seven; 12). ¶Log(minimum angle of resolution)=1·6. ||Data missing for 21 patients 
(four; seven; four; six). **Data missing for 30 patients (six; 11; eight; ﬁ ve). ††Data missing for 30 patients (six; 11; eight; ﬁ ve). ‡‡Data missing for 26 patients (six; nine; six; ﬁ ve). §§Data missing for 
39 patients (nine; 12; eight; ten). ¶¶Includes lesions with zero area (ie, not present); data missing for 45 patients (11; 14; nine; 11). ||||Number of eyes with non-zero lesion area. ***Data missing for 
14 patients (six; three; one; four). †††Data missing for 11 patients (two; two; three; four). ‡‡‡Score ranges from −9 (maximum negative eﬀ ect) to 3 (maximum positive eﬀ ect); data missing for 
91 patients (25; 20; 24; 22). §§§Score ranges from 0 to 72 (higher scores indicate higher satisfaction with treatment); data missing for 107 patients (29; 22; 28; 28).
Table 1: Outcomes at 2 years 
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lesion thick ness and the neurosensory retinal thickness 
including subretinal ﬂ uid did not diﬀ er signiﬁ cantly 
between drug groups but were signiﬁ cantly lower for 
participants assigned to continuous regimens than dis-
continuous regimens (ﬁ gure 2, table 1). The percentage of 
partici pants with ﬂ uid on OCT at 2 years was higher in 
the bevacizumab group than in the ranibizumab group 
(table 1), but the diﬀ erence was not signiﬁ cant (ﬁ gure 2). 
The percentage was signiﬁ cantly higher in the dis con-
tinuous treatment group than in the continuous treat-
ment group (ﬁ gure 2, table 1). Signiﬁ cantly more 
par tici pants in the discontinuous treatment group than 
the continuous treatment group had an active neovascular 
lesion at 2 years, but drug groups did not diﬀ er 
Figure 2: Secondary outcomes at 2 years
(A) By drug. (B) By regimen. 95% CIs given in parentheses and shown by bars. GMR=geometric mean ratio. MD=mean diﬀ erence. OR=odds ratio.
GMR
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(ﬁ gure 2, table 1). The percentage of participants with 
new geographic atrophy did not diﬀ er between drug 
groups (odds ratio [OR] 0·87, 95% CI 0·61–1·25; p=0·46), 
but was signiﬁ cantly lower in participants on dis con-
tinuous regimens than on continuous regimens (1·47, 
1·03–2·11; p=0·03; table 1). Median MacDQoL, MacTSQ, 
and EQ-5D state scores did not diﬀ er by drug (MacDQoL: 
p=0·74; MacTSQ: p=0·23; EQ-5D: p=0·51; appendix) or 
treatment regimen (p=0·73; p=0·47; p=0·64; appendix).
2 years after randomisation, the frequency of death 
(OR 0·96, 95% CI 0·46–2·02; p=0·91) or of an arterial 
thrombotic event or hospital admission for heart failure 
(1·69, 0·80–3·57; p=0·16) did not diﬀ er between drug 
groups (table 2, appendix). However, signiﬁ cantly more 
 Ranibizumab
(n=314)
Bevacizumab
(n=296)
Continuous regimen 
(n=308)
Discontinuous regimen 
(n=302)
Overall
(n=610)
Number 
of events
Aﬀ ected 
patients
Number 
of events
Aﬀ ected 
patients
Number 
of events
Aﬀ ected 
patients
Number 
of events
Aﬀ ected 
patients
Number 
of events
Aﬀ ected 
patients
Serious systemic event
Death by any cause* 15 15 (5%) 15 15 (5%) 10 10 (3%) 20 20 (7%) 30 30 (5%)
Arterial thrombotic event 13 13 (4%) 12 10 (3%) 7 7 (2%) 18 16 (5%) 25 23 (4%)
Non-fatal myocardial infarction† 4 4 (1%) 5 4 (1%) 2 2 (1%) 7 6 (2%) 9 8 (1%)
Non-fatal stroke 6 6 (2%) 3 3 (1%) 4 4 (1%) 5 5 (2%) 9 9 (1%)
Death from vascular causes 3 3 (1%) 4 4 (1%) 1 1 (<1%) 6 6 (2%) 7 7 (1%)
Arterial thrombotic event or heart failure 20 20 (6%) 14 12 (4%) 12 12 (4%) 22 20 (7%) 34 32 (5%)
Heart failure 7 7 (2%) 2 2 (1%) 5 5 (2%) 4 4 (1%) 9 9 (1%)
Venous thrombotic event 3 3 (1%) 4 4 (1%) 3 3 (1%) 4 4 (1%) 7 7 (1%)
Deep vein thrombosis 0 0 1 1 (<1%) 0 0 1 1 (<1%) 1 1 (<1%)
Pulmonary embolism 3 3 (1%) 3 3 (1%) 3 3 (1%) 3 3 (1%) 6 6 (1%)
Hospital admission for angina 7 7 (2%) 3 3 (1%) 6 6 (2%) 4 4 (1%) 10 10 (2%)
Hospital admission for non-ocular haemorrhage 3 3 (1%) 1 1 (<1%) 2 2 (1%) 2 2 (1%) 4 4 (1%)
Transient ischaemic attack‡ 1 1 (<1%) 1 1 (<1%) 0 0 2 2 (1%) 2 2 (<1%)
Any serious systemic event excluding non-vascular deaths ·· 31 (10%) ·· 19 (6%) ·· 21 (7%) ·· 29 (10%) ·· 50 (8%)
Any serious systemic event including non-vascular deaths ·· 38 (12%) ·· 28 (9%) ·· 27 (9%) ·· 39 (13%) ·· 66 (11%)
≥1 serious systemic event§ ·· 81 (26%) ·· 80 (27%) ·· 74 (24%) ·· 87 (29%) ·· 161 (26%)
MedDRA system organ class
Cardiac disorders¶ 20 20 (6%) 20 19 (6%) 16 16 (5%) 24 23 (8%) 40 39 (6%)
Gastrointestinal disorders 3 3 (1%) 10 9 (3%) 7 6 (2%) 6 6 (2%) 13 12 (2%)
General disorders and administration site conditions|| 15 15 (5%) 16 16 (5%) 10 10 (3%) 21 21 (7%) 31 31 (5%)
Infections and infestations 10 9 (3%) 16 12 (4%) 13 10 (3%) 13 11 (4%) 26 21 (3%)
Injury, poisoning, and procedural complications 12 12 (4%) 10 10 (3%) 10 10 (3%) 12 12 (4%) 22 22 (4%)
Neoplasms benign, malignant, and unspeciﬁ ed 
(including cysts and polyps)**
11 11 (4%) 16 14 (5%) 11 11 (4%) 16 14 (5%) 27 25 (4%)
Nervous system disorders 9 9 (3%) 8 8 (3%) 5 5 (2%) 12 12 (4%) 17 17 (3%)
Respiratory, thoracic, and mediastinal disorders†† 9 8 (3%) 7 7 (2%) 9 8 (3%) 7 7 (2%) 16 15 (2%)
Surgical and medical procedures‡‡ 16 16 (5%) 14 14 (5%) 14 14 (5%) 16 16 (5%) 30 30 (5%)
Vascular disorders 6 5 (2%) 6 6 (2%) 4 4 (1%) 8 7 (2%) 12 11 (2%)
Other 14 12 (4%) 15 14 (5%) 11 10 (3%) 18 16 (5%) 29 26 (4%)
Ocular event in the study eye
Uveitis 0 0 1 1 (<1%) 1 1 (<1%) 0 0 1 1 (<1%)
Retinal detachment 1 1 (<1%) 0 0 0 0 1 1 (<1%) 1 1 (<1%)
Cataract traumatic 1 1 (<1%) 1 1 (<1%) 1 1 (<1%) 1 1 (<1%) 2 2 (<1%)
Retinal pigment epithelial tear 3 3 (1%) 1 1 (<1%) 2 2 (1%) 2 2 (1%) 4 4 (1%)
Other 5 4 (1%) 3 3 (1%) 2 2 (1%) 6 5 (2%) 8 7 (1%)
≥1 ocular event ·· 8 (3%) ·· 6 (2%) ·· 6 (2%) ·· 8 (3%) ·· 14 (2%)
Any serious adverse event ·· 87 (28%) ·· 84 (28%) ·· 79 (26%) ·· 92 (30%) ·· 171 (28%)
Data are n or n (%). MedDRA=Medical Dictionary for Regulatory Activities. *Two in bevacizumab discontinuous group occurred >3 months after last visit. †One in bevacizumab discontinuous group occurred 
>3 months after last visit. ‡Not deﬁ ned as an expected serious adverse event in the protocol. §Includes any non-ocular serious adverse event. ¶One in bevacizumab discontinuous group occurred >105 days after 
last visit. ||Three in bevacizumab discontinuous group occurred >105 days after last visit. **One in bevacizumab discontinuous group occurred >105 days after last visit. ††One in bevacizumab discontinuous 
group occurred >105 days after last visit. ‡‡One in ranibizumab discontinuous group occurred >105 days after last visit.
Table 2: Serious adverse events within 2 years of recruitment
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patients on the dis continuous regimen than on the 
continuous regimen had died (OR 0·47, 95% CI 
0·22–1·03; p=0·05), although no diﬀ erence by regimen 
between frequency of an arterial thrombotic event or 
heart failure was recorded (0·56, 0·27–1·19; p=0·13; 
table 2, appendix).
Similar percentages of participants in the drug groups 
had at least one systemic SAE (p=0·82; table 2, appendix). 
Tests of the frequency of SAEs in diﬀ erent organ systems 
when there were more than ten participant-speciﬁ c 
events showed that SAEs coded as general disorders and 
adminis tration site conditions (which includes all deaths) 
diﬀ ered by treatment regimen (p=0·03) but not for 
any other organ system by drug or treatment regimen 
(table 2, appendix). SAEs coded as gastrointestinal were 
more frequent with bevacizumab than with ranibizumab 
(table 2), but the diﬀ erence was not signiﬁ cant (p=0·06; 
appendix) and was less than at 1 year.4 Serious ocular 
adverse events were rare (table 2, appendix).
The BCVA point estimate with pooled IVAN and CATT 
data showed that bevacizumab was non-inferior to 
ranibizumab, judged by the strict IVAN non-inferiority 
margin of 3·5 letters (ﬁ gure 3). Although the as needed 
treatment regimens diﬀ ered slightly, we decided to pool 
data for the two trials for this comparison. The dis-
continuous regimen was inferior to the continuous 
regimen (ﬁ gure 3). Pooled estimates of changes in total 
lesion thickness at the fovea showed no diﬀ erence between 
drugs, but favoured continuous treatment (p=0·001; 
appendix). New geographic atrophy was detected signiﬁ -
cantly more often during follow-up in participants on 
continuous than dis continuous regimens, but no diﬀ er-
ence between drugs was recorded (p=0·001; ﬁ gure 4). 
Pooled estimates of safety outcomes showed no diﬀ erences 
by drug for deaths or arterial thrombotic events but a 
signiﬁ cantly increased risk of any systemic SAE for 
bevacizumab (p=0·008; ﬁ gure 5). The com parison by 
regimen showed consistent increases in mortality 
(p=0·014) and the risk of any systemic SAE (p=0·063) with 
discontinuous treatment across trials (ﬁ gure 5).
Discussion
After 2 years in the IVAN trial, neither the comparison of 
bevacizumab with ranibizumab nor that of continuous 
with discontinuous regimens for BCVA was conclusive 
when judged against the prespeciﬁ ed non-inferiority 
margin of 3·5 letters. However, the mean diﬀ erences 
between groups, tending to favour ranibizumab and 
continuous treatment, were small and estimated to 
within 2·4 letters. Non-inferiority for both comparisons 
would have been established had we used the CATT 
non-inferiority margin of 5 letters. When we examined 
the pooled IVAN and CATT ﬁ ndings for BCVA, the 
point estimates were consistent. The increased precision 
gained with pooled data showed that bevacizumab was 
non-inferior to ranibizumab, but that discontinuous 
treatment was inferior to continuous treatment (panel). 
Nevertheless, even in the comparison between treatment 
regimens, the pooled mean diﬀ erence was small from a 
clinical perspective.
Figure 3: Change in best corrected distance visual acuity in CATT and IVAN at 2 years
(A) By drug. (B) By regimen. 95% CIs shown by bars. CATT=Comparison of Age-related macular degeneration 
Treatment Trials. IVAN=Inhibition of VEGF in Age-related choroidal Neovascularisation trial.
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Figure 4: Geographic atrophy in CATT and IVAN at 2 years
(A) By drug. (B) By regimen. 95% CIs shown by bars. CATT=Comparison of Age-related macular degeneration 
Treatment Trials. IVAN=Inhibition of VEGF in Age-related choroidal Neovascularisation trial.
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With respect to lesion morphology, we identiﬁ ed no 
signiﬁ cant diﬀ erences between drugs at 2 years, but 
consistent diﬀ erences favouring continuous treatment. 
The meta-analysis of total lesion thickness at the fovea 
conﬁ rmed these ﬁ ndings. Similar to the lesion metrics, 
we recorded no diﬀ erences in quality of life by drug, but 
near visual acuity and contrast sensitivity favoured a 
continuous regimen. Overall, the ﬁ ndings for the IVAN 
secondary visual function outcomes and the pooled 
ﬁ ndings for BCVA and lesion morphology consistently 
show that bevacizumab has similar eﬃ  cacy to rani-
bizumab. The ﬁ ndings also suggest that continuous 
treat ment every month gives slightly better visual func-
tion than does discontinuous treatment, although this 
improvement was not reﬂ ected in the primary outcome 
of BCVA or in self-reported health-related quality of life.
The CATT 2-year report5 suggested diﬀ erences between 
drugs and treatment regimens in the development of 
new geographic atrophy in the study eye during follow-
up. We found no diﬀ erence between drugs in the IVAN 
trial alone and when CATT and IVAN data were 
combined. However, our analysis showed a consistent 
and sub stantial increase in the risk of developing new 
geo graphic atropy with monthly compared with discon-
tinuous treat ment. This ﬁ nding raises the worrying 
possibility that any visual beneﬁ t from monthly treatment 
might not be maintained in the long term. 
For safety outcomes, our ﬁ nding that mortality was 
higher at 2 years with discontinuous treatment than 
continuous treatment is similar to the 1-year ﬁ ndings in 
CATT (pooled OR 0·49; p=0·014), as is increase in the risk 
of any systemic SAE (0·81; p=0·063). The comparisons of 
discontinuous and continuous regimens were not masked 
in either trial, but it seems implausible that bias should 
lead to an increased frequency of SAEs with discontinuous 
treatment. These worrying ﬁ ndings appear counter intui-
tive when viewed in a conventional dose-response frame-
work. However, in the context of biological therapies, the 
possibility of immunological sensitisation with inter-
mittent dosing needs to be considered.28
Neither the IVAN trial nor CATT was powered to 
detect diﬀ erences in harms of treatment. Hence, the 
meta-analyses provide the best summary of the 
available data. The comparisons between the drugs 
after 2 years are reassuring, with no suggestion of any 
diﬀ erence in mortality or arterial thrombotic events, 
which have pre viously been suggested to be related to 
use of anti-VEGF drugs. The pooled analysis for any 
systemic SAE seems to conﬁ rm an increased risk with 
bevacizumab, which was ﬁ rst reported in CATT.3,5 
However, the pooled analysis disguises the 
inconsistency between the separate trial estimates. 
Although the trials had similar ﬁ ndings at 1 year,4 the 
SAEs accruing in the second year in the IVAN trial 
shifted the 2-year OR almost to unity. Other ﬁ ndings 
for cardiovascular arterial thrombotic events from large 
analyses of routinely obtained data also vary29–31 and are 
at risk of confounding.32 Diﬀ erences between trials in 
masking of participants to drug allocation, which was 
achieved reliably only in the IVAN trial, could be a 
possible explanation. The accruing SAEs in our trial 
also provided improved precision for the pooled 
comparison by treat ment regimen (IVAN 2-year and 
CATT 1-year data), showing a signiﬁ cant diﬀ erence in 
mortality favouring continuous treatment, which is 
probably the ﬁ nding of greatest concern.
Figure 5: Safety outcomes in CATT and IVAN at 2 years
(A) By drug. (B) By regimen. 95% CIs shown by bars. CATT=Comparison of Age-related macular degeneration 
Treatment Trials. IVAN=Inhibition of VEGF in Age-related choroidal Neovascularisation trial.
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Our trial has important strengths. It was pragmatic, 
being done in the usual care setting in many hospitals in 
the UK National Health Service, and so directly informs 
the use of anti-VEGF drugs in similar settings. The 
bevacizumab product used in this trial was sourced from 
a compounding pharmacy that aliquoted and dispensed 
the drug, adhering to protocols for tests of potency and 
sterility approved by the Medicines and Healthcare 
products Regulatory Agency. Our ﬁ ndings should be 
generalised only to bevacizumab sourced from a manu-
facturing pharmacy that has quality-control processes to 
validate stability, potency, and sterility that have been 
approved by a drug regulatory agency.
The factorial design was eﬃ  cient and provided high 
statistical power for the primary outcome, despite the 
fact that the IVAN trial had only half as many partici-
pants as CATT. We studied a range of secondary 
functional outcomes that both support the visual acuity 
ﬁ ndings and describe the compromises when treatment 
is not continuous. We assessed the resources used to 
adminis ter treatment and previously reported that they 
were similar with either drug.4 Drug allocation was 
success fully masked and, in view of the elderly trial 
population, we had good retention. Sites failed to 
comply with the allocated treatment on only roughly 1% 
of visits (almost always relating to the treatment 
regimen) and, although most patients missed one or 
more visits, missed visits did not diﬀ er by group and 
most scheduled visits were attended.
The interpretation of the meta-analyses is limited by 
the appropriateness of pooling of available trials.33 We 
argue that, in this instance, the pooling of data was 
appropriate, because the studies were planned to be 
similar in design. We described our intention to pool 
data from the two trials in advance, and the CIs for the 
estimates from the studies overlap in all reported meta-
analyses. The meta-analyses of safety particularly were 
prompted by the IVAN and CATT data monitoring 
committees. Our descriptions of results from the two 
trials as consistent or inconsistent are subjective judg-
ments on the basis of the meta-analysis graphs.
Anti-VEGF drugs look set to remain the mainstay 
treatment for neovascular age-related macular degener-
ation for the foreseeable future, despite the rapid 
increase in potential new treatments. Concerns have 
been raised about the safety of aﬂ ibercept,34 despite 
evidence of eﬃ  cacy,6 and the results of brachytherapy in 
combination with anti-VEGF drugs have, so far, been 
disappointing.35 Photodynamic therapy or radiotherapy 
options used in combination might yet allow reductions 
in treatment frequency, but it will be important to study 
these treat ment strategies in comparison with monthly 
treatment, in view of our ﬁ nding of possible risks of 
discontinuous treatment.
In conclusion, the IVAN trial and meta-analyses of the 
CATT and IVAN data show that the choice of anti-VEGF 
treatment strategy is less straightforward than previously 
thought. Bevacizumab and ranibizumab have similar 
eﬃ  cacy and can be considered equivalent in this respect 
in the treatment of neovascular age-related macular 
degeneration. The increased risk of systemic SAEs and 
death with discontinuous treatment should probably 
outweigh the increased risk of new geographic atrophy 
that was recorded with monthly treatment. The slightly 
better functional outcomes with continuous treatment 
are a bonus. Continuous treatment also avoids the need 
to monitor disease activity on every visit. An important 
consideration when choosing to give treatment con-
tinuously is the high cost of ranibizumab,4 which may be 
unaﬀ ordable for publicly funded health systems.
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Panel: Research in context
Systematic review
We searched PubMed for reports of previous head-to-head trials with the terms 
“ranibizumab” (MeSH term or text), “bevacizumab” (MeSH term or text), and “macular 
degeneration” (major MeSH term), published in any language before July 3, 2013. We 
included only clinical or randomised controlled trials and identiﬁ ed systematic reviews 
comparing ranibizumab and bevacizumab. We searched Current Controlled Trials across 
several trial registers (“macular degeneration” and “ranibizumab”, “bevacizumab”, or 
“VEGF” in the title). We identiﬁ ed three trials other than CATT and the IVAN trial in which 
bevacizumab and ranibizumab have previously been compared.25–27 Two were single-centre 
trials25,27 and one a multicentre trial (the MANTA study26), but ﬁ ndings at 2 years had not 
been reported. Therefore, we only included the CATT and IVAN data in our meta-analyses.
Interpretation
IVAN and CATT are the ﬁ rst and largest multicentre head-to-head trials in which 
bevacizumab and ranibizumab for neovascular age-related macular degeneration have 
been compared. After 2 years in the IVAN trial, the comparisons of the eﬀ ect of the drugs 
and of discontinuous versus continuous treatment on best corrected visual acuity were 
inconclusive. However, when we pooled data from the two trials, bevacizumab was 
non-inferior to ranibizumab. It is now established that bevacizumab is not inferior to 
ranibizumab after 2 years of either continuous or discontinuous treatment with respect to 
visual acuity, and that total lesion thickness is also not signiﬁ cantly diﬀ erent by drug. With 
respect to systemic safety, there is no suggestion of any diﬀ erence between drugs in 
deaths or arterial thrombotic events at 2 years. As far as we are aware, visual function and 
safety with continuous versus discontinuous treatment has been compared only in CATT 
and the IVAN trial. Pooled data from the two trials shows that discontinuous treatment 
was inferior to continuous treatment for best corrected visual acuity. However, this 
diﬀ erence is not clinically important. There was a signiﬁ cant diﬀ erence in mortality 
favouring continuous treatment. Conversely, the risk of geographic atrophy increased 
with continuous treatment. The trade-oﬀ s should be discussed with patients. Overall, the 
available data show that the choice of anti-VEGF treatment strategy for neovascular 
age-related macular degeneration is less straightforward than previously thought. 
Bevacizumab and ranibizumab have similar eﬃ  cacy, but the diﬀ erence in mortality 
favouring continuous treatment means that continuous treatment might be preferable.
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